PhaseBio Pharmaceuticals, Inc. (PHAS) has 20 bekannte Insider- und institutionelle Anteilseigner verzeichnet. Der größte Anteilseigner ist NEW ENTERPRISE ASSOCIATES 13 LP mit 4,857,525 Aktien. Weitere bedeutende Anteilseigner sind Mow Jonathan P und Sharp John P.
PHAS Insider-Beteiligungen
Größter Aktionär
NEW ENTERPRISE ASSOCIATES 13 LP
4,857,525 Aktien
Käufe (12 Monate)
0
$0.00 Wert
Verkäufe (12 Monate)
0
$0.00 Wert
Top-Insider-Aktionäre
| # |
Name |
Funktion |
Gehaltene Aktien |
Zuletzt gemeldet |
Relative Größe |
| 1 |
New Enterprise Associates 13 Lp |
Director |
4,857,525 |
2022-10-26 |
|
| 2 |
Mow Jonathan P |
Chief Executive Officer |
132,502 |
2022-05-24 |
|
| 3 |
Sharp John P |
Chief Financial Officer |
65,767 |
2022-05-24 |
|
| 4 |
Arnold Susan Elizabeth |
SVP, Technical Operations |
41,236 |
2022-05-24 |
|
| 5 |
Tufts Linda |
Director |
36,000 |
2019-03-01 |
|
| 6 |
Lee John Sang |
Chief Medical Officer |
24,750 |
2022-02-28 |
|
| 7 |
Birchall Jonathan |
Chief Commercial Officer |
20,000 |
2022-05-24 |
|
| 8 |
Burkhardt Glen |
VP, Human Resources |
18,750 |
2022-02-28 |
|
| 9 |
Klein Peter Justin |
Director |
14,000 |
2021-06-04 |
|
| 10 |
Mukhopadhyay Bibhash |
Director |
11,000 |
2019-05-13 |
|
| 11 |
Ballance David James |
VP, Research and Sci. Affairs |
8,519 |
2020-11-23 |
|
| 12 |
Hanson Kristopher |
SVP and General Counsel |
8,463 |
2022-05-24 |
|
| 13 |
York Michael |
VP, Corporate Development |
7,059 |
2021-05-24 |
|
| 14 |
Hutson Nancy J |
Director |
4,000 |
2022-05-20 |
|
| 15 |
Sapir Alex |
Director |
3,750 |
2022-05-20 |
|
| 16 |
Thorp Clay |
Director |
3,750 |
2022-05-20 |
|
| 17 |
Harrigan Edmund |
Director |
3,750 |
2022-05-20 |
|
| 18 |
Loewy Caroline M |
Director |
3,750 |
2022-05-20 |
|
| 19 |
Van Den Broek Richard |
Director |
3,750 |
2022-05-20 |
|
| 20 |
Humphries William D. |
Director |
2,538 |
2022-06-10 |
|
Keine Beteiligungsdaten für PHAS verfügbar.
